Your browser doesn't support javascript.
loading
Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study.
Kristensen, Marie Skov; Green, Anders; Nybo, Mads; Hede, Simone Møller; Mikkelsen, Kristian Handberg; Gislason, Gunnar; Larsen, Mogens Lytken; Ersbøll, Annette Kjær.
Afiliação
  • Kristensen MS; National Institute of Public Health, University of Southern Denmark, Studiestræde 6, 1455, Copenhagen, Denmark.
  • Green A; Institute of Applied Economics and Health Research, N, 2200, Copenhagen, Denmark.
  • Nybo M; Open Patient data Explorative Network (OPEN), Odense University Hospital and University of Southern Denmark, Odense, Denmark.
  • Hede SM; Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark.
  • Mikkelsen KH; Institute of Applied Economics and Health Research, N, 2200, Copenhagen, Denmark.
  • Gislason G; Sanofi-Aventis Denmark A/S, Copenhagen, Denmark.
  • Larsen ML; National Institute of Public Health, University of Southern Denmark, Studiestræde 6, 1455, Copenhagen, Denmark.
  • Ersbøll AK; Department of Cardiology, The Cardiovascular Research Centre, Copenhagen University Hospital Herlev and Gentofte, Gentofte, Denmark.
BMC Cardiovasc Disord ; 20(1): 336, 2020 07 13.
Article em En | MEDLINE | ID: mdl-32660429
ABSTRACT

BACKGROUND:

Patients with acute coronary syndrome (ACS) are at high risk of recurrent cardiovascular (CV) event. The European guidelines recommend low-density lipoprotein cholesterol (LDL-C) levels < 1.8 mmol/L and early initiation of intensive lipid-lowering therapy (LLT) to reduce CV risk. In order to reduce the risk of further cardiac events, the study aimed to evaluate LDL-C goal attainment and LLT intensity in an incident ACS population.

METHODS:

A cohort study of patients with residency at Funen in Denmark at a first-ever ACS event registered within the period 2010-2015. Information on LLT use and LDL-C levels was extracted from national population registers and a Laboratory database at Odense University Hospital. Treatments and lipid patterns were evaluated during index hospitalization, at 6-month and 12-month follow-up.

RESULTS:

Among 3040 patients with an LDL-C measurement during index hospitalization, 40.7 and 39.0% attained the recommended LDL-C target value (< 1.8 mmol/L) within 6- and 12-month follow-up, respectively. During 6- and 12-month follow-up, a total of 89.2% (20.2%) and 88.4% (29.7%) used LLT (intensive LLT). Of the intensive LLT users, 43.4 and 47.7% reached the LDL-C target value at 6- and 12-month follow-up. The frequency of lipid monitoring was low 69.5, 77.7 and 53.6% in patients with a first-ever ACS during index hospitalization, 6- and 12-month follow-up, respectively.

CONCLUSION:

Using national health registers and laboratory data, a considerably gap was observed between treatment guidelines and clinical practice in the management of dyslipidemia leaving very high-risk patients without adequate lipid management strategy. Therefore, improved lipid management strategies aimed at reaching treatment targets are warranted.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dislipidemias / Síndrome Coronariana Aguda / Prevenção Secundária / LDL-Colesterol / Anticolesterolemiantes Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dislipidemias / Síndrome Coronariana Aguda / Prevenção Secundária / LDL-Colesterol / Anticolesterolemiantes Idioma: En Ano de publicação: 2020 Tipo de documento: Article